Published May 13, 2026 | 9:00 PM ⚊ Updated May 13, 2026 | 9:00 PM
The term, "polycystic ovary", made many patients believe that they had cysts, even when doctors were actually identifying immature follicles.
Synopsis: Polycystic Ovary Syndrome has been renamed Polyendocrine Metabolic Ovarian Syndrome after global experts concluded that the old term was medically inaccurate and misleading. The new name reflects the condition’s wider hormonal and metabolic impact, moving beyond the outdated focus on “ovarian cysts.”
For years, millions of women diagnosed with Polycystic Ovary Syndrome (PCOS) carried a name for their condition that explained little about what they were actually experiencing.
Many never had ovarian “cysts”. Instead, they dealt with insulin resistance, acne, irregular periods, infertility, obesity, anxiety, excessive hair growth, and metabolic complications that seemed entirely disconnected from the term PCOS.
Now, after what researchers described as an “unprecedented and comprehensive international health policy initiative,” the condition has officially been renamed PMOS — polyendocrine metabolic ovarian syndrome.
The ‘rechristening’ was announced through a paper published in The Lancet Health Policy, after years of global consultation involving clinicians, researchers, patient groups, and healthcare organisations.
According to the authors of the paper, the old term had become both scientifically inaccurate and clinically limiting, a name that no longer served the people carrying the diagnosis.
Also Read: Everything you need to know about India’s top 5 major cancers
The term, “polycystic ovary”, made many patients believe that they had cysts, even when doctors were actually identifying immature follicles on ultrasound scans. The Lancet paper was unambiguous on this point: the name “implies pathological ovarian cysts, which are not a feature of the condition”.
In reality, PCOS affects hormones, metabolism, cardiovascular health, skin, mental health, and fertility, making it far more systemic than the name ever suggested.
As the paper noted, the condition had long been “primarily perceived as a gynaecological or ovarian disorder”, despite decades of research showing otherwise.
The misperception had real consequences. Up to 70% of affected individuals remain undiagnosed, partly because the name failed to reflect the broad range of symptoms. Researchers linked this directly to “delayed diagnosis,” “fragmented care,” and poor awareness among both patients and healthcare providers.
The need to fix this issue had become urgent. As the authors put it, “the need to correct the inaccurate polycystic term, which implies pathological ovarian cysts, and recognise the multisystem features of the condition were prioritised by patient and health professional groups.”
Also Read: Women with PCOS at higher risk of developing eating disorders
The new name was adopted to reflect the science accurately, with each word chosen deliberately.
“Polyendocrine” refers to the multiple hormone systems involved, including insulin, androgens, ovarian hormones, and neuroendocrine pathways. Rather than an isolated ovarian disorder, the paper described PMOS as a condition involving “multiple interacting endocrine abnormalities”.
Evidence from genomic and endocrine studies showed that the term also covered neuroendocrine, metabolic, and reproductive pathways.
Hyperandrogenism — excess androgen levels — remains one of the defining diagnostic features. The paper noted that elevated ovarian and adrenal androgens contribute to acne, alopecia, hirsutism, and metabolic changes.
“Metabolic” was included because metabolic dysfunction is now considered central to the condition, not secondary to it.
As the authors wrote, “insulin resistance and compensatory hyperinsulinaemia, present in 85% of affected individuals, amplify androgen secretion and disrupt steroidogenesis, highlighting the metabolic-endocrine interplay.”
Notably, even among lean individuals with a BMI below 25, insulin resistance remained highly prevalent.
The researchers said that metabolic problems are deeply connected to PMOS — from how the condition begins in the body to the symptoms people experience later. “Metabolic abnormalities underpin PMOS, from genetic origins to clinical manifestations”, they said.
The associated risks are considerable: obesity, fatty liver disease, impaired glucose tolerance, type 2 diabetes, dyslipidaemia, hypertension, gestational diabetes, and increased odds of cardiovascular complications, including myocardial infarction and stroke.
“Collectively, this evidence shows that metabolic features are inherent in PMOS,” the authors wrote, adding that this “firmly endorses incorporation of the metabolic term in the revised nomenclature.”
“Ovarian” was retained because ovarian dysfunction remains a defining feature of the disorder. As the paper stated, “Ovarian dysfunction is a defining feature of PMOS, with genetic origins and disturbances in endocrine and paracrine function during and beyond reproductive life stages.”
Neuroendocrine abnormalities impair follicular maturation and disrupt ovarian steroid production, resulting in ovulatory dysfunction, menstrual irregularity, infertility, and the characteristic accumulation of small follicles seen on scans.
Researchers considered alternatives such as “reproductive” and “ovulatory,” but concluded that “ovarian” best captured the condition’s biological basis without overemphasising fertility alone.
Beyond the science, the paper gave significant weight to the emotional and social burden the old name had placed on patients.
Many participants in the global surveys said PCOS made them feel reduced to fertility issues, particularly in cultures where infertility carries deep social stigma.
The paper reported that “many individuals report distress associated with the name itself”, a finding that researchers took seriously throughout the renaming process.
Because of this, “avoidance of stigma” was established as one of the core principles guiding the new terminology. The authors also highlighted the importance of “meaningful language translation and cultural appropriateness” as key priorities for the global transition, particularly in settings where reproductive capability is closely tied to social expectations around womanhood.
The reproductive focus of the old name, the paper noted, could “reinforce stigma”, making an already difficult diagnosis harder to carry for many women around the world.
Calls to rename PCOS are not new. The US National Institutes of Health had flagged concerns about the term in 2012, but previous efforts consistently struggled to arrive at a consensus.
This time, researchers used global surveys, Delphi methods, workshops, and structured implementation planning to build lasting agreement.
More than 14,000 people, including patients and healthcare professionals, participated across different regions, alongside workshops involving around 90 representatives and 56 organisations. The report described the outcome as an “unprecedented, rigorous, multistep global consensus process.”
Crucially, when participants were asked to weigh familiarity against accuracy, they chose accuracy. Ultimately, the paper noted, participants prioritised “an accurate new name” rather than simply retaining the familiar PCOS acronym.
The condition does not change because of the changed name. Diagnostic criteria, treatment approaches, and management strategies will largely remain the same, including lifestyle management, hormonal treatment, fertility care, and metabolic monitoring.
But researchers felt the terminology shift could have a significant long-term impact. The paper argued that aligning the name with current science could improve “awareness, diagnosis, care quality, research coherence, and patient experience” across the board.
The transition from PCOS to PMOS will happen gradually over three years, with updates planned across medical guidelines, textbooks, disease classification systems, and electronic health records. Formal engagement with the World Health Organisation is also planned for adoption into the ICD disease classification system.
“This change has global implications for healthcare systems, policy, and research, and for advancing understanding and treatment of the condition,” the authors wrote.
The broader goal, the paper said in conclusion, is to achieve “greater awareness, enhanced diagnosis, improved care quality and patient satisfaction, and optimised outcomes across broad features of the condition”.
(Edited by Majnu Babu).
